MY177028A - Solid compositions of triglycerides and uses thereof - Google Patents

Solid compositions of triglycerides and uses thereof

Info

Publication number
MY177028A
MY177028A MYPI2016000861A MYPI2016000861A MY177028A MY 177028 A MY177028 A MY 177028A MY PI2016000861 A MYPI2016000861 A MY PI2016000861A MY PI2016000861 A MYPI2016000861 A MY PI2016000861A MY 177028 A MY177028 A MY 177028A
Authority
MY
Malaysia
Prior art keywords
solid compositions
triglycerides
triheptanoin
spray
drying
Prior art date
Application number
MYPI2016000861A
Inventor
John Klopp
Gabrielle Morris
Emil Kakkis
Steven Jungles
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of MY177028A publication Critical patent/MY177028A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)

Abstract

The present invention includes solid compositions of triglycerides with one or more fatty acids, such as triheptanoin and glycerol phenylbutyrate, and therapeutic use thereof. The solid compositions can be prepared by spray-drying or other processes. Figure 1
MYPI2016000861A 2013-11-14 2014-11-14 Solid compositions of triglycerides and uses thereof MY177028A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361904369P 2013-11-14 2013-11-14

Publications (1)

Publication Number Publication Date
MY177028A true MY177028A (en) 2020-09-02

Family

ID=53058066

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016000861A MY177028A (en) 2013-11-14 2014-11-14 Solid compositions of triglycerides and uses thereof

Country Status (18)

Country Link
US (3) US20160243071A1 (en)
EP (2) EP3782610A1 (en)
JP (3) JP2017501972A (en)
KR (1) KR102291310B1 (en)
CN (2) CN113181158A (en)
AR (1) AR099353A1 (en)
AU (1) AU2014348470B2 (en)
CA (2) CA3197154A1 (en)
CL (1) CL2016001130A1 (en)
ES (1) ES2833294T3 (en)
IL (1) IL245588B (en)
MX (2) MX2016006329A (en)
MY (1) MY177028A (en)
PE (1) PE20161024A1 (en)
PH (1) PH12016500821A1 (en)
RU (1) RU2016123169A (en)
TW (1) TWI640327B (en)
WO (1) WO2015073816A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20161024A1 (en) * 2013-11-14 2016-11-10 Ultragenyx Pharmaceutical Inc SOLID COMPOSITIONS OF TRIGLYCERIDES AND USES OF THEM
US20190076383A1 (en) * 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
CA3110724A1 (en) 2018-08-27 2020-03-05 Exerkine Corporation Method for treating lysosomal storage disease
US11583542B2 (en) * 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
CN113476408A (en) * 2021-07-23 2021-10-08 兆科药业（广州）有限公司 Phenylbutyrin granules and preparation method and application thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2800610B2 (en) * 1992-12-15 1998-09-21 不二製油株式会社 Production method of oil-in-water emulsion
JP3522843B2 (en) * 1994-07-29 2004-04-26 昭和産業株式会社 Lipo preparation
ES2157422T3 (en) 1995-02-07 2001-08-16 Brusilow Entpr Llc TRIGLICERIDS AND ETHYL ESTERS OF PHENYLALCANOIC ACID AND PHENYLALKYEN ACID USEFUL IN THE TREATMENT OF DIFFERENT DISORDERS.
JPH08311480A (en) * 1995-05-18 1996-11-26 D H Ee Kodo Seisei Chushutsu Gijutsu Kenkyu Kumiai Production of oil or fat comprising high-purify triacylglycerol and oil or fat composition containing highly unsaturated fatty acid
JP4902906B2 (en) * 1999-02-05 2012-03-21 ベイラー リサーチ インスティテュート Nutritional supplement or pharmaceutical preparation containing triglyceride containing fatty acid having 7 carbon atoms
US8399515B2 (en) * 2003-05-20 2013-03-19 Baylor Research Institute Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
US7141114B2 (en) * 2004-06-30 2006-11-28 Rec Silicon Inc Process for producing a crystalline silicon ingot
MX2007000304A (en) * 2004-07-02 2007-06-15 Baylor Res Inst Glycogen or polysaccharide storage disease treatment method.
KR20070113281A (en) * 2005-03-10 2007-11-28 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Antimicrobial compositions and methods
JP2008533048A (en) * 2005-03-10 2008-08-21 スリーエム イノベイティブ プロパティズ カンパニー How to treat ear infections
AU2007214127A1 (en) * 2006-02-10 2007-08-16 Sportscom Danmark Aps Coated tablets, their methods of preparation, and related uses
JP5296366B2 (en) * 2007-10-29 2013-09-25 日清オイリオグループ株式会社 Endurance improver for drugs and endurance drug
PL3133396T3 (en) 2008-04-29 2019-03-29 Horizon Therapeutics, Llc Methods of treatment using ammonia-scavenging drugs
MX2012014520A (en) * 2010-06-14 2013-03-05 Baylor Res Inst Triheptanoin diet for adult polyglucosan body disease (apbd) treatment.
CN101919453B (en) * 2010-08-16 2013-04-10 苏州市佳禾食品工业有限公司 Medium carbon chain fatty acid powder grease and preparation method thereof
KR20140094517A (en) 2011-09-30 2014-07-30 하이페리온 쎄라퓨틱스, 인크. Methods of therapeutic monitoring of nitrogen scavenging drugs
TWI572352B (en) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 Method for the preparation of triglycerides of medium-chain length fatty acids
WO2013158616A1 (en) * 2012-04-16 2013-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment of medium-chain acyl-coa dehydrogenase deficiency
BR112015013349A2 (en) 2012-12-13 2017-07-11 Baylor Res Institute At Dallas trieptanoin for the treatment of glucose transporter deficiency 1
PE20161024A1 (en) * 2013-11-14 2016-11-10 Ultragenyx Pharmaceutical Inc SOLID COMPOSITIONS OF TRIGLYCERIDES AND USES OF THEM

Also Published As

Publication number Publication date
TW201609189A (en) 2016-03-16
CN113181158A (en) 2021-07-30
EP3068383A4 (en) 2017-11-08
JP2022107017A (en) 2022-07-20
US20160243071A1 (en) 2016-08-25
PH12016500821A1 (en) 2016-06-13
JP2020111585A (en) 2020-07-27
US20200069631A1 (en) 2020-03-05
KR20160084407A (en) 2016-07-13
AU2014348470A1 (en) 2016-05-26
EP3782610A1 (en) 2021-02-24
US20230181513A1 (en) 2023-06-15
ES2833294T3 (en) 2021-06-14
AR099353A1 (en) 2016-07-20
TWI640327B (en) 2018-11-11
CA3197154A1 (en) 2015-05-21
IL245588B (en) 2021-08-31
PE20161024A1 (en) 2016-11-10
CN105764497A (en) 2016-07-13
CL2016001130A1 (en) 2017-01-20
IL245588A0 (en) 2016-06-30
RU2016123169A (en) 2017-12-19
MX2016006329A (en) 2016-09-06
MX2021001790A (en) 2021-04-19
EP3068383A1 (en) 2016-09-21
EP3068383B1 (en) 2020-09-16
CA2929688A1 (en) 2015-05-21
KR102291310B1 (en) 2021-08-23
JP2017501972A (en) 2017-01-19
AU2014348470B2 (en) 2020-01-30
WO2015073816A1 (en) 2015-05-21
CA2929688C (en) 2023-06-13

Similar Documents

Publication Publication Date Title
WO2015038796A3 (en) Secretion of heme-containing polypeptides
PH12016500587B1 (en) Octanoic, nonanoic and decanoic fatty acids with a pyrethroid adulticide
MX2019015311A (en) Cannabidiolic acid esters compositions and uses thereof.
MX2021001790A (en) Solid compositions of triglycerides and uses thereof.
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2014057362A3 (en) Omega -3 compositions
MX362349B (en) Minoxidil-containing hair growth composition.
SG10201907875TA (en) Modified meningococcal fhbp polypeptides
IN2014DN07483A (en)
SA515361092B1 (en) Racecadotril lipid compositions
EP3074000A4 (en) Suspension compositions of physiologically active phenolic compounds&methods of making and using the same
EP3068500A4 (en) Fertilizer compositions and methods of making and using the same
WO2015092810A3 (en) Amorphous form of idelalisib
IN2014DN11078A (en)
MX2017008450A (en) Microencapsulated nitrification inhibitor compositions.
EP3232770A4 (en) Generation of transgenic canola with low or no saturated fatty acids
MX369223B (en) Sunscreen compositions.
MX2018002514A (en) Modified cytotoxins and their therapeutic use.
WO2014165190A3 (en) Compositions comprising docosapentaenoic acid and methods of use
MY178960A (en) Hiv treatment formulation of atazanavir and cobicistat
MX370990B (en) Esters of oligo-hydroxycarboxylic acids and use thereof.
WO2014133811A3 (en) Compounds from invasive salvinias and methods of using the same
BR112016028561A8 (en) composition and dosage form comprising a marine oil comprising fatty acids, and use thereof
EP3027180A4 (en) Compositions and methods of the treatment of fatty acid metabolism disorders
WO2015073418A3 (en) Methods and assays for factor viii activity